Abstract 117P
Background
Radiofrequency ablation (RFA) helps to achieve R0 resection and may provide an alternative treatment for patients with unresectable colorectal liver metastases (CRLM) in combination with surgical resection. However, researches on efficacy and complication risks of hepatectomy combined with intraoperative RFA for multiple colorectal liver metastases (mCRLM) are limited.
Methods
From January 2013 and March 2017, patients who underwent hepatectomy alone (HA cohort) or hepatectomy combined with intraoperative RFA (HIR cohort) for mCRLM were retrospectively identified from Zhongshan Hospital affiliated to Fudan University. The mCRLM patients that were given ‘hepatectomy combined with intraoperative RFA’ were matched with those treated with hepatectomy alone via 1:1 propensity score (PS) matching. Recurrence-free survival (RFS) and overall survival (OS) after the initial hepatectomy were compared.
Results
After PSM, 252 patients were included (126 in each group). The HIR cohort had more grade I complications while no difference in higher grade complications (p = 0.231) and postoperative morbidity(p = 0.534) was detected. Total recurrence which includes intrahepatic and extrahepatic recurrence was no significantly difference in HIR cohort compared to HA cohort (p = 0.320). The median total RFS for HIG and HA was 10.47months and 10.7 months respectively (HR = 1.086 95% CI 0.766-1.540). The median OS for HIG and HA was 43.9 months and 46.1 months respectively (HR = 0.986 95% CI 0.648-1.307).
Conclusions
Hepatectomy combined with intraoperative RFA can be safely performed in mCRLM patients without an increased severe risk in the procedure and is representing a beneficial treatment to otherwise inoperable patients. The outcome of hepatectomy combined with intraoperative RFA is even comparable to hepatectomy alone after propensity score matching.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract